Articles On Micro-X (ASX:MX1)

ASX healthcare sector gains 1.99% in November while benchmark ASX 200 down 2.66% Mach7 rises 50% in November with health imaging stock outlining a growth strategy at its AGM  Island Pharmaceuticals rises after FDA confirms Galidesivir will...

ASX gains 23 points or 0.27% in choppy session of trade Real estate plunges 2.11% while banks and resources make strong gains Bond yields climb to highest level in 2025 on rate hike fears   ASX rides commodity wave higher The ASX 200 adde...

Micro-X debuts upgraded Rover mobile X-ray at the Radiological Society of North America annual meeting Enhanced Rover builds on Micro-X’s position in ultra-lightweight, motor-free mobile imaging Company also showcases its expanding pipelin...

Micro-X is adopting a partnership-led strategy to de-risk development of its world-leading cold cathode x-ray technology The company has secured around $80 million in funding in recent years to advance products including a portable Head CT...

ASX healthcare sector fell 4.83% in October and is down more than 19% YTD CSL shares fall more than 15% on October 28 after management trims FY26 guidance Nyrada surges 165% in October on board changes and progress in phase 2a trial    Wi...

ASX tech hits a speed bump in October New winners rise as old giants stumble Archer, Weebit and co keep the spark alive   October wasn’t kind to ASX tech investors. The S&P/ASX All Technology Index (XIJ) fell a hefty 8%, making it the...

Optiscan Imaging led the biotech pack in October, while some of the Big Four stocks were late scratchings Does CSL have an iron deficiency? Weebit Nano ‘mini me’ Dorsavi quietly jockeys for position in the high-stakes chip race   The ASX...

Host Fraser Palamara speaks with Professor Steven Davis from the Australian Stroke Alliance about the massive global impact of stroke and the technology reshaping how it’s treated. Stroke is the second leading cause of death worldwide, affe...

ASX health sector moved up 1.30% for the week, while broader market inched up 0.12% This week: PainChek’s groundbreaking digital app scored coveted FDA De Novo clearance; The FDA lifted a clinical hold on Neurizon’s lead drug candidate for...

If you have a high tolerance for risk, then it can be worth having a few small cap ASX shares in a balanced portfolio. But which ones could be buys? Fortunately, the team at Morgans has done the hard work for you by picking out two small ca...

ASX holds firm as oil spills, gold dips and tech sector surges Cannon-Brookes stirs up AGL climate clash DigiCo Eagers and Mesoblast fly high   By the close of Friday, the ASX’s 0.46% gain looked pretty darn respectable considering oil’s...

Highlights Tech and healthcare lead early ASX trading momentum Small caps dominate headlines with strong project updates Energy and resources remain under pressure amid commodity shifts Tech and healthcare stocks lifte...

Highlights: Key ASX-listed companies report milestone updates Healthcare, infrastructure, defence and consumer segments advance Market resilience holds despite global uncertainty ASX market strengthened this week as Di...

Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds. In this episode, host Tylah Tully unpacks the latest news from Micro-X (ASX:MX1), who have received a $3.3 million dollar order from the Malaysian Governm...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

Mag 7 drive Wall Street’s best September in years
 ASX tech takes a beating while DroneShield soars
 I Synergy strikes Octagram deal to chase Web3 frontier   Mag 7 carries the load in September September has historically been the weakest...

ASX 200 down just 3 points, All Ords up 0.7 points Defensive stocks bulwark ASX against US government shut down China-BHP stoush and lithium losses weigh on materials sector ASX plays it safe as US government shutdown kicks off The ASX 2...

First of three Micro-X Head CT test benches completed and ready for installation at an Australian hospital to begin stroke imaging trials Pivotal study to run over six to nine months comparing Head CT images with conventional CT scans of s...

Highlights Hot inflation dampens expectations for easing monetary policy Banks, resources, and tech stocks weighed on the broader ASX stock market Select mining and energy players delivered upbeat exploration and project upd...

Current cancer imaging tools are “not good enough”, Imagion chief Bob Proulx says Micro-x announces second grant in the space of two days Race Oncology wins Korean trial assent … in South Korea, of course   Imagion Biosystems (ASX:IBX) sa...

Micro-X awarded $4.4 million Australian government grant to build and trial an ambulance with its Head CT device to detect stroke Company plans a full patient imaging trial to collect data from stroke patients transported in the stroke amb...

MoneyTalks is Stockhead’s drill down into what stocks investors are looking at right now. We tap our list of experts to hear what’s hot, their top picks and what they’re looking out for. In this edition we hear from senior healthcare analys...

The S&P ASX 200 Health Care index fell 13.21% in August as a tough reporting season weighed on sector CSL had its biggest ever one day fall on August 19, down 17% following softer FY25 results and restructure plans Despite the broader...

Earnings fire S&P to fresh highs AI halo fades as semis stumble ASX tech slides 1.7pc in August   What happened in August? By the end of August, 98% of S&P 500 companies had reported Q2 earnings, and 81% beat expectations. That al...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin FNArena's Monitor keeps track of corporate earnings result releases, including broke...

Miniaturised X-rays open new markets for ASX-listed Micro-X Head CT for stroke diagnosis to enter Australian hospital trials in coming months US deals show the company’s tech can scale internationally   Special Report: An Aussie innovato...

  In the medical device sector, sometimes trial news can excite investors more than the approval endgame At the application stage, devices have a much higher chance of being approved than drugs Investors can expect news from several compa...

Morgans’ Scott Power describes mood at Bioshares Biotech Summit as “markedly more upbeat than prior years” with signs of a rotation back to ASX healthcare sector Power highlights nine ASX healthcare companies from summit with clear near-te...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

ASX heath sector falls 0.65 % in past five days but returns 9% in July in a strong comeback  ‘Mostly pretty good’ June quarterly reporting season comes to end  Clarity Pharmaceuticals completes $203 million capital raise to institutional i...

Highlights ASX posts broad-based gains amid slowing inflation Financials and retail stocks lead positive movement Strategic updates boost emerging sector companies Australia's equity market witnessed a strong trading s...

June CPI comes in at 0.7pc, annual inflation at 2.1pc Broad market strength across six sectors Banks move higher on interest rate cut anticipation   Soft inflation read points to likely rate cut The ASX wasn’t in bad shape by midmorning,...

Let’s check in with what HotCopper users are closely watching at lunchtime. Given that we’re basically on the deadline before companies get a scolding if they don’t report updates, on Wednesday, the ASX announcements list is basically o...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

ASX health up 1.6% over five days as Morgans’ Scott Power says the mood is positive for start of FY26 Wound management house Tetratherix make its ASX debut and breaks an IPO drought for sector ProMedicus surges past $300 for first time fol...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

S&P500 and Nasdaq hit new highs on Big Tech run
 ASX energy leads, but tech holds strong in June
 Defence stocks dominate as DroneShield, Elsight, archTIS surge   Wall Street wrapped up the quarter on a strong note, with both the S&am...

ASX heath sector falls 1.1% over past five days The US FDA approves CSL’s Andembry to prevent attacks of hereditary angioedema Clever Culture systems records its second consecutive quarter of positive cashflow operations Healthcare and li...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

ASX tech rockets 22pc in May Elsight, EROAD, Etherstack and Yojee fly 4DS goes vertical after chip conference   The ASX tech sector didn’t just rally in May, it rocketed. Up more than 22%, it was one of the biggest monthly leaps in recent...

TechnologyOne becomes Canberra’s digital backbone ‘Buy Australian Plan’ aims to make it easier to land a public sector contract ASX tech stocks with signed government deals   The third largest technology stock on the ASX, Technology One (...

ASX heath sector falls 1.3%, trailing ASX 200 up 1.1% as macro picture remains uncertain but ‘little bit better’ Soft-tissue repair company Aroa Biosurgery reconfirms FY25 reported revenue guidance of NZ$81-84 million Medical imaging softe...

Many life science companies stress the virtue of diversity: multiple programs to protect against one of them failing. Diversity can be helpful: after its failed phase III eye disease programs, Opthea would be wishing it had another drug can...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

Tech gets its groove back with help from Wall Street and RBA Defence tech darlings like WhiteHawk and Elsight grab the spotlight Harvest Tech goes global, Droneshield fires again   In April 2025, the ASX tech sector finally got its mojo b...

ASX tech sector hit hard by global turmoil Big names on Nasdaq struggle as AI investments raise doubts ASX listed Opyl, Yojee, RocketBoots lead in March   In March, the S&P/ASX 200 Information Technology sector (XIJ) took a big hit, m...

ASX heath sector falls 2.1%, while broader markets rise 0.8% for the same period Opthea phase III Coast trial into wet AMD fails to meet primary and secondary endpoints  EMVision starts pivotal validation trial for emu bedside brain scanne...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

February chaos hit, Trump’s tariffs rocked markets ASX tech fell hard, WiseTech led the crash EP&T and Envirosuite led gainer, Spacetalk cut losses   February, a month that’s historically been no stranger to chaos, wrapped up with a d...